Pharvaris NV (FRA:9EN) Volatility: 39.34% (As of Jul. 11, 2026)


FRA:9EN Pharvaris NV FRA:9EN
28 GF Score
Price €30.70
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Volatility?

Pharvaris NV FRA:9EN -1.76% 28 Volatility is 39.34% as of Jul. 11, 2026. GuruFocus rates FRA:9EN with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-07-11), Pharvaris NV's Volatility is 39.34%.

Pharvaris NV  (FRA:9EN) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Pharvaris NV Volatility Related Terms

FRA:9EN vs BHVN, NRIX, VCEL: Volatility Comparison

For the Biotechnology subindustry, Pharvaris NV's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Volatility distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Volatility falls into.


FRA:9EN
28GF Score
Pharvaris NV FRA:9EN
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV  (FRA:9EN) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 39.34% mean?
Pharvaris NV (FRA:9EN) has a Volatility of 39.34% as of Jul. 11, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Pharvaris NV and its competitors.
Is Pharvaris NV's Volatility too high?
Pharvaris NV's current Volatility is 39.34%. Overall, Pharvaris NV has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Volatility compare to BHVN and NRIX?
Pharvaris NV's Volatility of 39.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Pharvaris NV and its competitors. Pharvaris NV's current Volatility is 39.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current Volatility of 39.34%. The current Volatility is 39.34%. Pharvaris NV's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current Volatility is 39.34% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges PHVS:USA
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score

Get the complete analysis for FRA:9EN

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.70
Price